Capping Prescription Costs Act of 2025

4/6/2025, 2:18 PM
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Bill 119 HR 2553, also known as the "Prescription Drug Cost Sharing Limitation Act," aims to address the rising costs of prescription drugs by limiting the amount that individuals are required to pay out-of-pocket for their medications. The bill seeks to provide relief to consumers who are struggling to afford necessary medications by capping the amount of cost-sharing that insurance companies can impose.

Under the provisions of the bill, insurance plans would be required to limit the amount that individuals are required to pay for prescription drugs to a certain percentage of the total cost. This would help to prevent individuals from facing exorbitant costs for necessary medications, particularly for those with chronic conditions who rely on multiple prescriptions.

In addition to limiting cost-sharing, the bill also includes provisions aimed at increasing transparency in drug pricing and promoting competition in the pharmaceutical industry. By requiring drug manufacturers to disclose pricing information and encouraging the development of generic alternatives, the bill seeks to lower overall drug costs for consumers. Overall, Bill 119 HR 2553 represents a bipartisan effort to address the growing issue of prescription drug affordability in the United States. By limiting cost-sharing, increasing transparency, and promoting competition, the bill aims to make prescription medications more accessible and affordable for all Americans.
Congress
119

Number
HR - 2553

Introduced on
2025-04-01

# Amendments
0

Sponsors
+5

Cosponsors
+5

Variations and Revisions

4/1/2025

Status of Legislation

Bill Introduced
Introduced to House
House to Vote
Introduced to Senate
Senate to Vote

Purpose and Summary

Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Bill 119 HR 2553, also known as the "Prescription Drug Cost Sharing Limitation Act," aims to address the rising costs of prescription drugs by limiting the amount that individuals are required to pay out-of-pocket for their medications. The bill seeks to provide relief to consumers who are struggling to afford necessary medications by capping the amount of cost-sharing that insurance companies can impose.

Under the provisions of the bill, insurance plans would be required to limit the amount that individuals are required to pay for prescription drugs to a certain percentage of the total cost. This would help to prevent individuals from facing exorbitant costs for necessary medications, particularly for those with chronic conditions who rely on multiple prescriptions.

In addition to limiting cost-sharing, the bill also includes provisions aimed at increasing transparency in drug pricing and promoting competition in the pharmaceutical industry. By requiring drug manufacturers to disclose pricing information and encouraging the development of generic alternatives, the bill seeks to lower overall drug costs for consumers. Overall, Bill 119 HR 2553 represents a bipartisan effort to address the growing issue of prescription drug affordability in the United States. By limiting cost-sharing, increasing transparency, and promoting competition, the bill aims to make prescription medications more accessible and affordable for all Americans.
Alternative Names
Official Title as IntroducedTo limit cost-sharing for prescription drugs, and for other purposes.

Policy Areas
Health

Comments

Recent Activity

Latest Action4/1/2025
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall w...